Dupilumab for the treatment of severe asthma： a rapid health technology assessment

WANG Huayu; DONG Shichao; SUN Wei; WANG Ying

doi:10.6039/j.issn.1001-0408.2025.06.02

您当前的位置：

首页 >

文章列表页 >

Dupilumab for the treatment of severe asthma： a rapid health technology assessment

更新时间：2025-09-25

- Dupilumab for the treatment of severe asthma： a rapid health technology assessment
- ZHONGGUO YAOFANG Vol. 36, Issue 6, Pages: 648-654(2025)
- 作者机构：
  
  1.天津医科大学第二医院药学部，天津　300211
  2.天津医科大学第二医院呼吸内科，天津　300211
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2025.06.02
  CLC： R974+.3;R562.2+5;R969.3
- Received：23 September 2024，
  
  Revised：2025-01-15，
  
  Accepted：15 January 2025，
  
  Published：30 March 2025
- 稿件说明：
移动端阅览
王华玉,董士超,孙伟,等.度普利尤单抗治疗重度哮喘的快速卫生技术评估[J].中国药房,2025,36(06):648-654.

WANG Huayu,DONG Shichao,SUN Wei,et al.Dupilumab for the treatment of severe asthma： a rapid health technology assessment[J].ZHONGGUO YAOFANG,2025,36(06):648-654.
王华玉,董士超,孙伟,等.度普利尤单抗治疗重度哮喘的快速卫生技术评估[J].中国药房,2025,36(06):648-654. DOI： 10.6039/j.issn.1001-0408.2025.06.02.

WANG Huayu,DONG Shichao,SUN Wei,et al.Dupilumab for the treatment of severe asthma： a rapid health technology assessment[J].ZHONGGUO YAOFANG,2025,36(06):648-654. DOI： 10.6039/j.issn.1001-0408.2025.06.02.

摘要

目的

采用快速卫生技术评估（HTA）的方法，评价度普利尤单抗治疗重度哮喘的有效性、安全性和经济性，为临床治疗提供循证依据。

方法

检索PubMed、Cochrane Library、中国知网、万方和维普网等数据库及HTA机构官网，收集度普利尤单抗治疗重度哮喘的HTA报告、系统评价/Meta分析和药物经济学研究。筛选文献、提取数据并评估文献质量后，对文献结果进行描述性分析。

结果

共纳入15篇文献，包括9篇系统评价/Meta分析和6篇药物经济学研究。有效性方面，度普利尤单抗显著优于安慰剂。与其他生物制剂比较，在12岁及以上的重度哮喘患者中，对于嗜酸性粒细胞（EOS）≥300个/μL的人群，度普利尤单抗改善第1秒用力呼气容积（FEV

）的作用排第1位，优于特泽鲁单抗、贝那利珠单抗和美泊利珠单抗；减少哮喘急性发作的作用排第2位，仅次于特泽鲁单抗；而改善哮喘控制问卷评分的作用排名比较靠后，仅优于贝那利珠单抗。对于150个/μL≤EOS＜300个/μL的人群，度普利尤单抗对哮喘急性发作的改善情况优于美泊利珠单抗，而对FEV

的改善作用弱于贝那利珠单抗和美泊利珠单抗。安全性方面，度普利尤单抗与安慰剂及其他生物制剂的不良事件和严重不良事件发生率的差异无统计学意义，但其注射部位反应的发生率显著高于安慰剂。经济性方面，各国研究结果不一致，尚缺乏我国的研究数据。

结论

度普利尤单抗用于重度哮喘具有良好的有效性和安全性，经济性有待基于我国医疗环境进一步研究。

Abstract

OBJECTIVE

To evaluate the efficacy， safety and cost-effectiveness of dupilumab in the treatment of severe asthma with rapid health technology assessment （HTA）， and to provide evidence-based evidence for clinical treatment.

METHODS

Retrieved from PubMed，Cochrane Library，CNKI，Wanfang， VIP database， and other related websites of HTA. HTA reports， systematic review/meta-analysis， and economic studies of dupilumab in the treatment of severe asthma were collected. Researchers independently identified literature， extracted data， and assessed the quality of included studies. Qualitative description was performed.

RESULTS

A total of 15 pieces of literature were included， involving 9 systematic reviews/meta-analyses and 6 economic studies. In terms of effectiveness， dupilumab was significantly better than placebo. Compared with other biological drugs， in the patients with severe asthma aged 12 years and above， for those with eosinophil （EOS） ≥300 cells/μL， dupilumab ranked first in improving forced expiratory volume in one second （FEV

）， outperforming tezepelumab， benralizumab， and mepolizumab. It ranked second in reducing acute exacerbations， surpassed only by tezepelumab， while its effect on improving asthma control questionnaire score was relatively lower， being better only than benralizumab. For those with 150 cells/μL ≤EOS＜300 cells/μL， dupilumab was superior to mepolizumab in reducing asthma exacerbation， while the effect on FEV

was weaker than benralizumab and mepolizumab. In terms of safety， there was no significant difference in the incidence of adverse events and serious adverse events between dupilumab and placebo or other biological drugs， while the incidence of injection site reactions of dupilumab was significantly higher than placebo. In terms of cost-effectiveness， the research results of different countries were not consistent， and there was a lack of research data from China.

CONCLUSIONS

Dupilumab is an effective and safe choice in the treatment of severe asthma， and its cost-effectiveness requires further research based on China’s medical environment to be determined.

关键词

Keywords

references

中华医学会呼吸病学分会哮喘学组 . 支气管哮喘防治指南：2020年版 [J ] . 中华结核和呼吸杂志， 2020 ， 43 （ 12 ）： 1023 - 1048 .

Asthma Group of Chinese Thoracic Society . Guidelines for bronchial asthma prevention and management：2020 edition [J ] . Chin J Tuberc Respir Dis ， 2020 ， 43 （ 12 ）： 1023 - 1048 .

LIN J T ， WANG W Y ， CHEN P ， et al . Prevalence and risk factors of asthma in mainland China：the CARE study [J ] . Respir Med ， 2018 ， 137 ： 48 - 54 .

王文雅，林江涛，周新，等 . 我国＞14岁重症哮喘患者的临床特征和患病危险因素 [J ] . 中华医学杂志， 2020 ， 100 （ 14 ）： 1106 - 1111 .

WANG W Y ， LIN J T ， ZHOU X ， et al . A survey on clinical characteristics and risk factors of severe asthma in China [J ] . Natl Med J China ， 2020 ， 100 （ 14 ）： 1106 - 1111 .

BUSH A ， FITZPATRICK A M ， SAGLANI S ， et al . Difficult-to-treat asthma management in school-age children [J ] . J Allergy Clin Immunol Pract ， 2022 ， 10 （ 2 ）： 359 - 375 .

Global Initiative for Asthma . Global strategy for asthma management and prevention [EB/OL ] .（ 2024-05-22 ）[ 2024-08-31 ] . https：//ginasthma.org/wp-content/uploads/2024/05/GINA-2024-Strategy-Report-24_05_22_WMS.pdf https://ginasthma.org/wp-content/uploads/2024/05/GINA-2024-Strategy-Report-24_05_22_WMS.pdf .

Chronic Airway Disease Professional Committee of China Medical Education Association ， China Asthma Alliance . China expert consensus on diagnosis and treatment of severe asthma：2024 [J ] . Natl Med J China ， 2024 ， 104 （ 20 ）： 1759 - 1789 .

ISRAEL E ， REDDEL H K . Severe and difficult-to-treat asthma in adults [J ] . N Engl J Med ， 2017 ， 377 （ 10 ）： 965 - 976 .

袁胜芳，宋宁，王布，等 . 成人重度支气管哮喘生物靶向治疗研究进展 [J ] . 中华结核和呼吸杂志， 2020 ， 43 （ 4 ）： 376 - 379 .

YUAN S F ， SONG N ， WANG B ， et al . Research progress of biological target therapy for adult severe bronchial asthma [J ] . Chin J Tuberc Respir Dis ， 2020 ， 43 （ 4 ）： 376 - 379 .

LE FLOC’H A ， ALLINNE J ， NAGASHIMA K ， et al . Dual blockade of IL-4 and IL-13 with dupilumab，an IL-4Rα antibody，is required to broadly inhibit type 2 inflammation [J ] . Allergy ， 2020 ， 75 （ 5 ）： 1188 - 1204 .

嵇承栋，朱琳懿，万悦竹，等 . 国际卫生技术评估机构协作网卫生技术评估报告清单解读 [J ] . 中国循证医学杂志， 2016 ， 16 （ 3 ）： 369 - 372 .

JI C D ， ZHU L Y ， WAN Y Z ， et al . An introduction of reporting checklist of health technology assessment deve-loped by the International Network of Agencies for Health Technology Assessment [J ] . Chin J Evid Based Med ， 2016 ， 16 （ 3 ）： 369 - 372 .

熊俊，陈日新 . 系统评价/Meta分析方法学质量的评价工具AMSTAR [J ] . 中国循证医学杂志， 2011 ， 11 （ 9 ）： 1084 - 1089 .

XIONG J ， CHEN R X . An introduction to a measurement tool to assess the methodological quality of systematic reviews/meta-analysis：AMSTAR [J ] . Chin J Evid Based Med ， 2011 ， 11 （ 9 ）： 1084 - 1089 .

张苏贤，张天嵩 . 中西医结合治疗非小细胞肺癌系统评价/Meta分析方法学质量评价 [J ] . 中国循证医学杂志， 2016 ， 16 （ 10 ）： 1231 - 1235 .

ZHANG S X ， ZHANG T S . Methodological quality assessment of systematic reviews and meta-analysis in fields of integrated Chinese-western therapy for non-small cell lung cancer [J ] . Chin J Evid Based Med ， 2016 ， 16 （ 10 ）： 1231 - 1235 .

HUSEREAU D ， DRUMMOND M ， AUGUSTOVSKI F ， et al . Consolidated health economic evaluation reporting standards 2022 （CHEERS 2022） statement：updated reporting guidance for health economic evaluations [J ] . Value Health ， 2022 ， 25 （ 1 ）： 3 - 9 .

徐欢欢，苏鹏丽，郭文勇，等 . 近十年中成药药物经济学研究文献分析及质量评价 [J ] . 中国药物经济学， 2023 ， 18 （ 11 ）： 5 - 10，16 .

XU H H ， SU P L ， GUO W Y ， et al . Pharmacoeconomics research literature analysis and quality evaluation of Chinese patent medicine in recent ten years [J ] . China J Pharm Econ ， 2023 ， 18 （ 11 ）： 5 - 10，16 .

柯义君，王威，黄灿，等 . 维立西呱治疗心力衰竭有效性、安全性及经济性的快速卫生技术评估 [J ] . 中国药房， 2024 ， 35 （ 15 ）： 1818 - 1824 .

KE Y J ， WANG W ， HUANG C ， et al . Rapid health technology assessment of the efficacy，safety and cost-effectiveness of vericiguat in the treatment of heart failure [J ] . China Pharm ， 2024 ， 35 （ 15 ）： 1818 - 1824 .

NOPSOPON T ， LASSITER G ， CHEN M L ， et al . Comparative efficacy of tezepelumab to mepolizumab，benralizumab，and dupilumab in eosinophilic asthma：a Bayesian network meta-analysis [J ] . J Allergy Clin Immunol ， 2023 ， 151 （ 3 ）： 747 - 755 .

阮俊文，周建荣，刘惟优，等 . 度普利尤单抗治疗支气管哮喘疗效和安全性的Meta分析 [J ] . 临床荟萃， 2023 ， 38 （ 10 ）： 869 - 877 .

RUAN J W ， ZHOU J R ， LIU W Y ， et al . Meta-analysis of the efficacy and safety of dupilumab on the treatment of bronchial asthma [J ] . Clin Focus ， 2023 ， 38 （ 10 ）： 869 - 877 .

蔡宇良 . 度普利尤单抗在治疗支气管哮喘中的疗效与安全性的Meta分析 [D ] . 广州：广东医科大学， 2023 .

CAI Y L . Meta-analysis of efficacy and safety of dupi-lumab in the treatment of bronchial asthma [D ] . Guangzhou ： Guangdong Medical University ， 2023 .

AKENROYE A ， LASSITER G ， JACKSON J W ， et al . Comparative efficacy of mepolizumab，benralizumab，and dupilumab in eosinophilic asthma：a Bayesian network meta-analysis [J ] . J Allergy Clin Immunol ， 2022 ， 150 （ 5 ）： 1097 - 1105.e12 .

ANDO K ， FUKUDA Y ， TANAKA A ， et al . Comparative efficacy and safety of tezepelumab and other biologics in patients with inadequately controlled asthma according to thresholds of type 2 inflammatory biomarkers：a syste-matic review and network meta-analysis [J ] . Cells ， 2022 ， 11 （ 5 ）： 819 .

ZAAZOUEE M S ， ALWARRAQI A G ， MOHAMMED Y A ， et al . Dupilumab efficacy and safety in patients with moderate to severe asthma：a systematic review and meta-analysis [J ] . Front Pharmacol ， 2022 ， 13 ： 992731 .

ANDO K ， TANAKA A ， SAGARA H . Comparative efficacy and safety of dupilumab and benralizumab in patients with inadequately controlled asthma：a systematic review [J ] . Int J Mol Sci ， 2020 ， 21 （ 3 ）： 889 .

XIONG X F ， ZHU M ， WU H X ， et al . Efficacy and safety of dupilumab for the treatment of uncontrolled asthma：a meta-analysis of randomized clinical trials [J ] . Respir Res ， 2019 ， 20 （ 1 ）： 108 .

ZAYED Y ， KHEIRI B ， BANIFADEL M ， et al . Dupilumab safety and efficacy in uncontrolled asthma：a systematic review and meta-analysis of randomized clinical trials [J ] . J Asthma ， 2019 ， 56 （ 10 ）： 1110 - 1119 .

ALI A ， GARCÍA E ， TORRES-DUQUE C A ， et al . Cost-effectiveness analysis of dupilumab versus omalizumab，mepolizumab，and benralizumab added to the standard of care in adults with severe asthma in Colombia [J ] . Expert Rev Pharmacoecon Outcomes Res ， 2024 ， 24 （ 3 ）： 361 - 374 .

MAREQUE M ， CLIMENTE M ， MARTINEZ-MORAGON E ， et al . Cost-effectiveness of benralizumab versus mepolizumab and dupilumab in patients with severe uncontrolled eosinophilic asthma in Spain [J ] . J Asthma ， 2023 ， 60 （ 6 ）： 1210 - 1220 .

XU X ， SCHAEFER C ， SZENDE A ， et al . A cost comparison of benralizumab，mepolizumab，and dupilumab in patients with severe asthma：a US third-party payer perspective [J ] . J Manag Care Spec Pharm ， 2023 ， 29 （ 11 ）： 1193 - 1204 .

TOHDA Y ， MATSUMOTO H ， MIYATA M ， et al . Cost-effectiveness analysis of dupilumab among patients with oral corticosteroid-dependent uncontrolled severe asthma in Japan [J ] . J Asthma ， 2022 ， 59 （ 11 ）： 2162 - 2173 .

BUENDÍA J A ， PATIÑO D G . Cost-utility analysis of dupilumab add on therapy versus standard therapy in adolescents and adults for severe asthma in Colombia [J ] . Expert Rev Pharmacoecon Outcomes Res ， 2022 ， 22 （ 4 ）： 575 - 580 .

BUENDÍA J A ， PATIÑO D G . Dupilumab in children with moderate-to-severe asthma：a cost utility analysis [J ] . Pediatr Pulmonol ， 2022 ， 57 （ 10 ）： 2313 - 2319 .

HOLGUIN F ， CARDET J C ， CHUNG K F ， et al . Management of severe asthma：a European Respiratory Society/American Thoracic Society guideline [J ] . Eur Respir J ， 2020 ， 55 （ 1 ）： 1900588 .

齐军，吴倩，李森，等 . 哮喘控制问卷与哮喘生命质量问卷在哮喘患者中的应用价值研究 [J ] . 国际呼吸杂志， 2014 ， 34 （ 3 ）： 174 - 176 .

QI J ， WU Q ， LI S ， et al . Application value of the asthma control questionnaire and asthma quality of life questionnaire in patients with asthma [J ] . Int J Respir ， 2014 ， 34 （ 3 ）： 174 - 176 .

WECHSLER M E ， FORD L B ， MASPERO J F ， et al . Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma（TRAVERSE）：an open-label extension study [J ] . Lancet Respir Med ， 2022 ， 10 （ 1 ）： 11 - 25 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Tenecteplase in the treatment of acute ischemic stroke： a rapid health technology assessment

Rapid health technology assessment of dapagliflozin in the treatment of type 2 diabetes mellitus combined with cardiovascular disease

Rapid health technology assessment of lorlatinib in the treatment of non-small cell lung cancer

Rapid health technology assessment of baloxavir marboxil in the treatment of influenza

Rapid health technology assessment of linaclotide in the treatment of constipated irritable bowel syndrome

Related Author

LI Huiting

MEN Peng

ZHANG Zhetao

ZHANG Jin

DENG Xiaomei

SHI Tianlu

WANG Yubo

CHEN Ji

Related Institution

Dept. of Pharmacy， the First Affiliated Hospital of USTC （Anhui Provincial Hospital）

Anhui Provincial Key Laboratory of Precision Pharmaceutical Preparations and Clinical Pharmacy

Dept. of Pharmacy， Peking University Third Hospital

Institute for Drug Evaluation， Peking University Health Science Center

Dept. of Pharmacy， the First Affiliated Hospital of Xinjiang Medical University

Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰